T1	Participants 177 242	Cutaneous Lymphoma Task Force phase III randomized clinical trial
T2	Participants 569 624	patients treated with PUVA alone or PUVA and bexarotene
T3	Participants 767 821	patients with stage IB and IIA mycosis fungoides (MF).
T4	Participants 1060 1082	93 randomized patients
